Market Currents
More on Teva (TEVA -2.1%) Q4: net profit -37% to $320M as revenue falls 7.5%. U.S. sales -14% to...
-
Thursday, February 7, 9:03 AM ETMore on Teva (TEVA -2.1%) Q4: net profit -37% to $320M as revenue falls 7.5%. U.S. sales -14% to $2.6B amid a sharp fall in Provigil (sleep disorder) due to generic competition. Copaxone global revenues +14% to $1.1B, but faces increasing competition. Expects to launch 23 generic drugs in 2013, as in 2012. Reiterates 2013 revenue forecast of $19.5-20.5B and adjusted EPS of $4.85-5.15. Declares dividend of 1.15 shekels (31 cents) a share, +15% from Q3.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
This news story has 2 comments: